The firm, launched in May by WuXi Healthcare Ventures and Frontline BioVentures, is looking to raise $450m for its first US fund, according to a regulatory filing.

6 Dimensions Capital, the strategic investment vehicle formed by pharmaceutical firm WuXi PharmaTech and venture capital firm Frontline BioVentures, is raising a $450m fund, according to a securities filing yesterday.

WuXi PharmaTech combined its WuXi Healthcare Ventures unit with Frontline in May this year to create an entity with roughly $800m of assets under management.

The deal was closed alongside an announcement that 6 Dimensions intended to raise both dollar and renminbi-denominated funds. The dollar fund in question would…